These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21243744)

  • 21. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Women's awareness of ovarian cancer risks and symptoms.
    Lockwood-Rayermann S; Donovan HS; Rambo D; Kuo CW
    Am J Nurs; 2009 Sep; 109(9):36-45; quiz 46. PubMed ID: 19704232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recommendations for treatment of individuals at risk for hereditary breast and ovarian carcinoma].
    Radulović S; Branković-Magić M; Janković R; Ristanović M
    Srp Arh Celok Lek; 2003; 131(7-8):345-50. PubMed ID: 14692152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
    Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
    Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
    Kwon JS; Daniels MS; Sun CC; Lu KH
    J Clin Oncol; 2010 Feb; 28(4):675-82. PubMed ID: 19841329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal.
    Tinelli A; Malvasi A; Leo G; Vergara D; Pisanò M; Ciccarese M; Chiuri VE; Lorusso V
    Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.
    McLemore MR; Aouizerat B
    Biol Res Nurs; 2005 Apr; 6(4):262-7. PubMed ID: 15788735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
    Wolff TA; Wilson JE
    Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
    [No Abstract]   [Full Text] [Related]  

  • 30. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
    Geisler JP; Hatterman-Zogg MA; Rathe JA; Lallas TA; Kirby P; Buller RE
    Hum Mutat; 2001 Oct; 18(4):337-44. PubMed ID: 11668617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A terrible beauty: a physician's story of ovarian cancer.
    Spano LJ
    Can Fam Physician; 2007 Jun; 53(6):983-5. PubMed ID: 17872763
    [No Abstract]   [Full Text] [Related]  

  • 32. 'Indirect' BRCA1/2 testing: a useful approach in hereditary breast and ovarian cancer families without a living affected relative.
    Cruger DG; Kruse TA; Gerdes AM
    Clin Genet; 2005 Sep; 68(3):228-33. PubMed ID: 16098011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pros and cons of genetic testing for breast and ovarian cancer risk.
    Frank TS; Braverman AM
    Int J Fertil Womens Med; 1999; 44(3):139-45. PubMed ID: 10435912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hereditary ovarian cancer.
    Russo A; Calò V; Bruno L; Rizzo S; Bazan V; Di Fede G
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):28-44. PubMed ID: 18656380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate, Breast and Ovarian Cancer Genetic Risk Assessment: Connecting the Dots.
    Gomella LG
    Can J Urol; 2016 Oct; 23(5):8429. PubMed ID: 27705725
    [No Abstract]   [Full Text] [Related]  

  • 36. [Ovarian cancer screening of high risk groups].
    Tropé C
    Tidsskr Nor Laegeforen; 2000 Aug; 120(18):2191. PubMed ID: 11006746
    [No Abstract]   [Full Text] [Related]  

  • 37. [Screening for ovarian cancer].
    Apold J; Heimdal K; Møller P
    Tidsskr Nor Laegeforen; 2000 Jun; 120(16):1913-4. PubMed ID: 10925628
    [No Abstract]   [Full Text] [Related]  

  • 38. London hospital widens access to genetic tests for ovarian cancer.
    Arie S
    BMJ; 2014 Jan; 348():g1179. PubMed ID: 24474303
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
    Havrilesky LJ; Sanders GD; Kulasingam S; Chino JP; Berchuck A; Marks JR; Myers ER
    Cancer; 2011 Feb; 117(3):545-53. PubMed ID: 21254049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Progress of the Specific and Rapid Genetic Detection Methods for Ovarian Cancer Diagnosis and Treatment.
    Dong K; Zhang W; Cheng S; Shu W; Zhao R; Wang H
    Technol Cancer Res Treat; 2022; 21():15330338221114497. PubMed ID: 36062718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.